SET domain-containing protein 4 (SETD4)

SET domain-containing protein 4 (SETD4) is an epigenetic lysine methyltransferase enzyme that catalyzes methylation of lysine residues on histones (notably H4K20) and certain non-histone proteins (e.g., KU70 at lysine-570)[1][2][4][5]. SETD4 plays a critical role in maintaining quiescence of stem and progenitor cells, regulation of cell cycle and proliferation, response to tissue injury, and modulation of apoptosis. In cancer, SETD4 is upregulated in some tumor types (particularly ER-negative breast cancer) and may confer pro-survival or quiescent properties to cancer stem cells[1][2][3]. Genetic manipulation of SETD4 in animal models affects recovery from bone marrow injury and tumorigenesis[1][3]. SETD4 is a member of class VII SET domain proteins, sharing structural similarity with SETD3 and SETD6, but with distinct substrate specificity for non-histone proteins as well as histones[1][2]. Its gene is located on chromosome 21, with multiple isoforms generated via alternative splicing[1][5]. No approved drugs currently target SETD4 directly, but it represents a potential therapeutic target for future cancer and regenerative medicine strategies[1][2][3][5]. Key functional and safety concerns would arise from targeting SETD4 given its broad roles in cell proliferation, survival, and tissue repair.

Other names

SETD4SET domain containing 4C21orf18C21orf27

Inhibition of lysine methyltransferase activity (targeting methylation of histones/non-histone proteins); Modulation of cell quiescence and apoptosis pathways; Epigenetic modulation impacting cell cycle and stem cell maintenance